Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Nov;38(11):1910-1916.
doi: 10.1111/jgh.16265. Epub 2023 Jun 19.

Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease

Andree H Koop  1 , Paul M Travers  2 , Sahil Khanna  3 , Darrell S Pardi  3 , Francis A Farraye  1 , Jana G Hashash  1   4
Affiliations
Multicenter Study

Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease

Andree H Koop et al. J Gastroenterol Hepatol. 2023 Nov.

Abstract

Background and aim: Although fidaxomicin is an effective first-line treatment for Clostridioides difficile infection, it has not been well studied in patients with inflammatory bowel disease. We aimed to assess the effectiveness of fidaxomicin for the treatment of C. difficile infection in patients with inflammatory bowel disease.

Methods: This was a multicenter retrospective study of adults with inflammatory bowel disease and C. difficile infection treated with fidaxomicin with at least 3 months of follow up. The primary outcomes were treatment response, defined as resolution of C. difficile infection-attributed diarrhea and/or negative C. difficile infection stool test, and time to C. difficile infection recurrence after fidaxomicin.

Results: Thirty-three patients (median age 42 years; 60.6% female) were included. Most patients had ulcerative colitis (26, 78.8%), were receiving treatment with a biologic or small molecule medication (19, 57.6%), and had a prior episode of C. difficile infection (26, 78.8%, median 2 episodes, range 0-15). Fidaxomicin led to resolution of C. difficile infection in 20 (60.6%) patients, with 6/20 (30.0%) developing a recurrence at a median of 55 days. Most patients who failed to respond to fidaxomicin underwent fecal microbiota transplantation (10/13, 76.9%) with resolution.

Conclusions: In this cohort of patients with inflammatory bowel disease and C. difficile infection, 60.6% responded to treatment with fidaxomicin. Of those who did not respond, fecal microbiota transplantation was an effective therapy.

Keywords: Clostridioides difficile infection; Crohn's disease; fidaxomicin; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

References

    1. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat. Rev. Dis. Primers. 2016; 2: 16020.
    1. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am. J. Gastroenterol. 2021; 116: 1124-1147.
    1. Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res. 2021; 19: 265-274.
    1. Hashash JG, Binion DG. Managing Clostridium difficile in inflammatory bowel disease (IBD). Curr. Gastroenterol. Rep. 2014; 16: 393.
    1. Anderson A, Click B, Ramos-Rivers C et al. Lasting impact of Clostridium difficile infection in inflammatory bowel disease: a propensity score matched analysis. Inflamm. Bowel Dis. 2017; 23: 2180-2188.

Publication types

LinkOut - more resources